Clinical Trials Browser

Phase 2 × OTHER_GOV × lorlatinib × Clear all

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung